{"organizations": [], "uuid": "ac7950bc94755751b90d4f7e501e0b1efa691d24", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/gilead-sciences-results/gilead-hepatitis-c-drug-sales-slump-shares-fall-6-percent-idUSL1N1S814Y", "country": "US", "domain_rank": 408, "title": "Gilead hepatitis C drug sales slump, shares fall 6 percent", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T23:25:00.000+03:00", "replies_count": 0, "uuid": "ac7950bc94755751b90d4f7e501e0b1efa691d24"}, "author": "", "url": "https://www.reuters.com/article/gilead-sciences-results/gilead-hepatitis-c-drug-sales-slump-shares-fall-6-percent-idUSL1N1S814Y", "ord_in_thread": 0, "title": "Gilead hepatitis C drug sales slump, shares fall 6 percent", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "gilead", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "gilead sciences inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1, 2018 / 8:27 PM / Updated 11 minutes ago Gilead hepatitis C drug sales slump, shares fall 6 percent Reuters Staff 2 Min Read\nMay 1 (Reuters) - Gilead Sciences Inc reported a lower quarterly profit on Tuesday as sales of its flagship hepatitis C drugs fell by a greater-than-expected 59 percent, sending shares of the biotechnology company down nearly 6 percent.\nGilead said it earned $1.48 a share in the first quarter excluding onetime items. Analysts, on average, expected an adjusted profit of $1.67 a share, according to Thomson Reuters I/B/E/S.\nNet income fell to $1.5 billion, or $1.17 per share, from $2.7 billion, or $2.05 per share, a year earlier. Revenue fell 22 percent to $5.08 billion.\nQuarterly sales of Gileadâ€™s hepatitis C drugs dropped to $1.05 billion from $2.58 billion a year earlier, falling short of the $1.19 billion average analyst forecast. Sales of other antiviral and HIV drugs rose slightly to $3.33 billion from $3.27 billion.\nShares of Gilead, which rose half a percent to close at $72.56 in regular trading on the Nasdaq, were down 5.6 percent at $68.50 after hours. (Reporting by Deena Beasley; editing by Jonathan Oatis)", "external_links": [], "published": "2018-05-01T23:25:00.000+03:00", "crawled": "2018-05-01T23:42:31.010+03:00", "highlightTitle": ""}